MedTrace Logo

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

NCT03227432 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-08-14

No results posted yet for this study

Summary

This research study is studying a combination of targeted therapies as a possible treatment for multiple myeloma (MM).

The drugs involved in this study are:

* Elotuzumab
* Nivolumab
* Pomalidomide
* Dexamethasone

Conditions

Interventions

DRUG

Dexamethasone

Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.

DRUG

Pomalidomide

Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.

DRUG

Elotuzumab

Elotuzumab is an antibody, that stimulates the immune system to fight diseases

DRUG

Nivolumab

Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer

Sponsors & Collaborators

Principal Investigators

  • Jacob Laubach, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-31
Primary Completion
2021-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03227432 on ClinicalTrials.gov